Company news
Cellectar Biosciences, Inc. news in 2019
Cellectar Biosciences, Inc.'s news releases, calls and decks from 2019, newest first.
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
December 15, 2019
Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference
December 1, 2019
Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
November 11, 2019
Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
October 16, 2019
Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
October 7, 2019
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma
September 23, 2019
Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
September 15, 2019
Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
September 9, 2019
Decks in 2019
- Investor Presentation (January 2019)
Investor deck · 30 slides · Jan 29, 2019
- Investor Presentation (January 2019)
Investor deck · 33 slides · Jan 7, 2019